Health-related Quality of Life with Encorafenib plus Binimetinib for BRAFV600E Thyroid Cancer

20260 citationsJournal Articlediamond Open Access

Authors

Naomi Kiyota · Kobe University Hospital

Makoto Tahara · National Cancer Center Hospital East

Hiroo Imai · Tohoku University Hospital

Shunji Takahashi · The Cancer Institute Hospital

Akihiro Nishiyama · Kanazawa University Hospital

Shingo Tamura · National Kyushu Medical Center

Yasushi Shimizu

Abstract

Combination therapy of encorafenib plus binimetinib for unresectable BRAF V600-mutated thyroid cancer was associated with generally maintained HR-QoL. Considering the efficacy and safety data from the trial, the regimen may provide clinical benefits while maintaining HR-QoL.

Topics & Keywords

Thyroid Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Melanoma and MAPK Pathways

Publication Details

Published in: European Thyroid Journal

DOI: 10.1530/etj-25-0273

Field-Weighted Citation Impact: 0.00

Command Palette

Health-related Quality of Life with Encorafenib plus Binimetinib for BRAFV600E Thyroid Cancer

Authors

Abstract

Topics & Keywords

Publication Details